Long-term treatment of allogeneic adipose-derived stem cells in a dog with rheumatoid arthritis
- Author:
Min-Gyeong SEO
1
;
Seil PARK
;
Seonyoung HAN
;
Ah-Young KIM
;
Eun-Joo LEE
;
Kyu-Shik JEONG
;
Il-Hwa HONG
Author Information
- Publication Type:Original Article
- From:Journal of Veterinary Science 2022;23(4):e61-
- CountryRepublic of Korea
- Language:English
-
Abstract:
Background:Although there are growing demands for stem cell-based therapy for companion animals in various diseases, a few clinical trials have been reported. Moreover, most of them are the results from only one or a few times of stem cell injection.
Objectives:The aim of this study is to describe a long-term treatment with allogeneic adipose-derived stem cells (ASCs) in a dog with rheumatoid arthritis (RA), which is a rare canine disease.
Methods:The dog with RA received intravascular injection of allogeneic ASCs derived from two healthy donors once a month for 11 months. To assess therapeutic effects of ASCs, orthopedic examination and clinical evaluation was performed. Cytokines of tumor necrosis factor-α and interleukin-6 in the plasma were measured using ELISA analysis.
Results:Despite this repeated and long-term administration of allogeneic ASCs, there were no side effects such as immunorejection responses or cell toxicity. The orthopedic examination score for the dog decreased after ASCs treatment, and the clinical condition of the dog and owner’s satisfaction were very good
Conclusions:Although ASCs has been suggested as one of the options for RA treatment because of its anti-inflammatory and immunosuppressive functions, it has never been used to treat RA in dogs. The present report describes a case of canine RA treated with allogeneic ASCs for long-term in which the dog showed clinical improvement without adverse effects.
